BioCentury
DATA GRAPHICS | Product Development

Next-gen NK cell enhancements in the clinic

Companies are turning to tumor targeting, IL-15 expression and alternate cell sourcing to boost the potency and longevity of NK cell therapies

May 20, 2022 7:18 PM UTC

NK cell companies are using a range of engineering, combination and sourcing strategies to increase the cancer therapies’ potency and durability. Nkarta’s recent clinical data bolsters the idea that CAR and cytokine expression could provide the boost NK cell therapies need to compete with CAR Ts.

NK cells have been a bright spot for biotech in 2022, as data suggest next-generation, off-the-shelf versions of the cells, once considered a safer yet less effective alternative to T cells, may now have similar efficacy. ...





Complimentary access available. Register for a free account.

Already have an account? Log in